{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:24:43Z","timestamp":1787163883066,"version":"build-2736575974"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH132019"],"award-info":[{"award-number":["R01MH132019"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"U.S. Department of Health & Human Services | NIH | National Institute of Mental Health","doi-asserted-by":"publisher","award":["R01MH137057"],"award-info":[{"award-number":["R01MH137057"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015503","name":"Lieber Institute for Brain Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015503","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"DOI":"10.1038\/s41380-026-03824-9","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:31:00Z","timestamp":1787160660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The therapeutic potential of COMT inhibition: cognition and beyond"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2966-2281","authenticated-orcid":false,"given":"Elizabeth M.","family":"Tunbridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6091-6729","authenticated-orcid":false,"given":"Gregory V.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2409-2969","authenticated-orcid":false,"given":"Daniel R.","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"3824_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-psych-113011-143750","volume":"64","author":"A Diamond","year":"2013","unstructured":"Diamond A. Executive functions. Annu Rev Psychol. 2013;64:135\u201368. https:\/\/doi.org\/10.1146\/annurev-psych-113011-143750","journal-title":"Annu Rev Psychol"},{"key":"3824_CR2","doi-asserted-by":"crossref","unstructured":"Fuster JM The Prefrontal Cortex, 5th Edition. Elsevier. London; 2015.","DOI":"10.1016\/B978-0-12-407815-4.00002-7"},{"key":"3824_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.tics.2018.12.006","volume":"23","author":"T Ott","year":"2019","unstructured":"Ott T, Nieder A. Dopamine and cognitive control in prefrontal cortex. Trends Cogn Sci. 2019;23:213\u201334. https:\/\/doi.org\/10.1016\/j.tics.2018.12.006","journal-title":"Trends Cogn Sci"},{"key":"3824_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/s0165-0173(99)00045-4","volume":"31","author":"PS Goldman-Rakic","year":"2000","unstructured":"Goldman-Rakic PS, Muly IEC, Williams GV. D1 receptors in prefrontal cells and circuits. Brain Res Rev. 2000;31:295\u2013301. https:\/\/doi.org\/10.1016\/s0165-0173(99)00045-4","journal-title":"Brain Res Rev"},{"key":"3824_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev.neuro.24.1.167","volume":"24","author":"EK Miller","year":"2001","unstructured":"Miller EK, Cohen JD. An intergrative theory of prefrontal cortex function. Annu Rev Neurosci. 2001;24:167\u2013202. https:\/\/doi.org\/10.1146\/annurev.neuro.24.1.167","journal-title":"Annu Rev Neurosci"},{"key":"3824_CR6","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1016\/j.biopsych.2011.01.027","volume":"69","author":"AFT Arnsten","year":"2011","unstructured":"Arnsten AFT. Catecholamine Influences on dorsolateral prefrontal cortical networks. Biol Psychiatry. 2011;69:e89\u2013e99. https:\/\/doi.org\/10.1016\/j.biopsych.2011.01.027","journal-title":"Biol Psychiatry"},{"key":"3824_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1124\/pr.108.000869","volume":"63","author":"AS Kristensen","year":"2011","unstructured":"Kristensen AS, Andersen J, J\u00f8rgensen TN, S\u00f8rensen L, Eriksen J, Loland CJ, et al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev. 2011;63:585\u2013640. https:\/\/doi.org\/10.1124\/pr.108.000869","journal-title":"Pharmacol Rev"},{"key":"3824_CR8","doi-asserted-by":"publisher","first-page":"7188","DOI":"10.1038\/s41380-021-01194-y","volume":"26","author":"C Korn","year":"2021","unstructured":"Korn C, Akam T, Jensen KHR, Vagnoni C, Huber A, Tunbridge EM, et al. Distinct roles for dopamine clearance mechanisms in regulating behavioral flexibility. Mol Psychiatry. 2021;26:7188\u201399. https:\/\/doi.org\/10.1038\/s41380-021-01194-y","journal-title":"Mol Psychiatry"},{"key":"3824_CR9","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1523\/jneurosci.18-07-02697.1998","volume":"18","author":"SR Sesack","year":"1998","unstructured":"Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci. 1998;18:2697\u2013708. https:\/\/doi.org\/10.1523\/jneurosci.18-07-02697.1998","journal-title":"J Neurosci"},{"key":"3824_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/cne.1092","volume":"432","author":"DA Lewis","year":"2001","unstructured":"Lewis DA, Melchitzky DS, Sesack SR, Whitehead RE, Auh S, Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol. 2001;432:119\u201336. https:\/\/doi.org\/10.1002\/cne.1092","journal-title":"J Comp Neurol"},{"key":"3824_CR11","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41593-023-01566-3","volume":"27","author":"A Mohebi","year":"2024","unstructured":"Mohebi A, Wei W, Pelattini L, Kim K, Berke JD. Dopamine transients follow a striatal gradient of reward time horizons. Nat Neurosci. 2024;27:737\u201346. https:\/\/doi.org\/10.1038\/s41593-023-01566-3","journal-title":"Nat Neurosci"},{"key":"3824_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2004.05.006","volume":"74","author":"JK Seamans","year":"2004","unstructured":"Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol. 2004;74:1\u201358. https:\/\/doi.org\/10.1016\/j.pneurobio.2004.05.006","journal-title":"Prog Neurobiol"},{"key":"3824_CR13","doi-asserted-by":"publisher","first-page":"7731","DOI":"10.1073\/pnas.95.13.7731","volume":"95","author":"ZU Khan","year":"1998","unstructured":"Khan ZU, Mrzljak L, Gutierrez A, de la Calle A, Goldman-Rakic PS. Prominence of the dopamine D2 short isoform in dopaminergic pathways. Proc Natl Acad Sci. 1998;95:7731\u20136. https:\/\/doi.org\/10.1073\/pnas.95.13.7731","journal-title":"Proc Natl Acad Sci"},{"key":"3824_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/35041572","volume":"408","author":"A Usiello","year":"2000","unstructured":"Usiello A, Baik JH, Roug\u00e9-Pont F, Picetti R, Dierich A, LeMeur M, et al. Distinct functions of the two isoforms of dopamine D2 receptors. Nature. 2000;408:199\u2013203. https:\/\/doi.org\/10.1038\/35041572","journal-title":"Nature"},{"key":"3824_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/978-3-7091-9211-5_8","volume":"36","author":"PS Goldman-Rakic","year":"1992","unstructured":"Goldman-Rakic PS, Lidow MS, Smiley JF, Williams MS. The anatomy of dopamine in monkey and human prefrontal cortex. J neural Transm Suppl. 1992;36:163\u201377. https:\/\/doi.org\/10.1007\/978-3-7091-9211-5_8","journal-title":"J neural Transm Suppl"},{"key":"3824_CR16","doi-asserted-by":"publisher","first-page":"10553","DOI":"10.1523\/jneurosci.18-24-10553.1998","volume":"18","author":"EC Muly","year":"1998","unstructured":"Muly EC, Szigeti K, Goldman-Rakic PS. D1 receptor in interneurons of macaque prefrontal cortex: distribution and subcellular localization. J Neurosci. 1998;18:10553\u201365. https:\/\/doi.org\/10.1523\/jneurosci.18-24-10553.1998","journal-title":"J Neurosci"},{"key":"3824_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1093\/cercor\/3.3.223","volume":"3","author":"JF Smiley","year":"1993","unstructured":"Smiley JF, Goldman-Rakic PS. Heterogeneous targets of dopamine synapses in monkey prefrontal cortex demonstrated by serial section electron microscopy: a laminar analysis using the Silver-enhanced Diaminobenzidine Sulfide (SEDS) immunolabeling technique. Cereb Cortex. 1993;3:223\u201338. https:\/\/doi.org\/10.1093\/cercor\/3.3.223","journal-title":"Cereb Cortex"},{"key":"3824_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/cne.20601","volume":"488","author":"L Negyessy","year":"2005","unstructured":"Negyessy L, Goldman\u2010Rakic PS. Subcellular localization of the dopamine D2 receptor and coexistence with the calcium\u2010binding protein neuronal calcium sensor\u20101 in the primate prefrontal cortex. J Comp Neurol. 2005;488:464\u201375. https:\/\/doi.org\/10.1002\/cne.20601","journal-title":"J Comp Neurol"},{"key":"3824_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00213-006-0527-8","volume":"191","author":"CC Lapish","year":"2007","unstructured":"Lapish CC, Kroener S, Durstewitz D, Lavin A, Seamans JK. The ability of the mesocortical dopamine system to operate in distinct temporal modes. Psychopharmacology. 2007;191:609\u201325. https:\/\/doi.org\/10.1007\/s00213-006-0527-8","journal-title":"Psychopharmacology"},{"key":"3824_CR20","doi-asserted-by":"publisher","first-page":"19900","DOI":"10.1073\/pnas.1116727109","volume":"109","author":"K D\u2019Ardenne","year":"2012","unstructured":"D\u2019Ardenne K, Eshel N, Luka J, Lenartowicz A, Nystrom LE, Cohen JD. Role of prefrontal cortex and the midbrain dopamine system in working memory updating. Proc Natl Acad Sci. 2012;109:19900\u20139. https:\/\/doi.org\/10.1073\/pnas.1116727109","journal-title":"Proc Natl Acad Sci"},{"key":"3824_CR21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.tins.2004.08.002","volume":"27","author":"G Winterer","year":"2004","unstructured":"Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 2004;27:683\u201390. https:\/\/doi.org\/10.1016\/j.tins.2004.08.002","journal-title":"Trends Neurosci"},{"key":"3824_CR22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/376572a0","volume":"376","author":"GV Williams","year":"1995","unstructured":"Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine Dl receptors in prefrontal cortex. Nature. 1995;376:572\u20135. https:\/\/doi.org\/10.1038\/376572a0","journal-title":"Nature"},{"key":"3824_CR23","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1093\/cercor\/bhw244","volume":"27","author":"T Ott","year":"2016","unstructured":"Ott T, Nieder A. Dopamine D2 receptors enhance population dynamics in primate prefrontal working memory circuits. Cereb Cortex. 2016;27:4423\u201335. https:\/\/doi.org\/10.1093\/cercor\/bhw244","journal-title":"Cereb Cortex"},{"key":"3824_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1146\/annurev-clinpsy-081219-111203","volume":"18","author":"M Luciana","year":"2022","unstructured":"Luciana M, Collins PF. Neuroplasticity, the prefrontal cortex, and psychopathology-related deviations in cognitive control. Annu Rev Clin Psychol. 2022;18:443\u201369. https:\/\/doi.org\/10.1146\/annurev-clinpsy-081219-111203","journal-title":"Annu Rev Clin Psychol"},{"key":"3824_CR25","doi-asserted-by":"publisher","unstructured":"Cools R, Frob\u00f6se M, Aarts E, Hofmans L. Dopamine and the motivation of cognitive control. In: Dopamine and the Motivation of Cognitive Control. Handbook of Clinical Neurology. 2019;123:43\u2013163. Elsevier. Amsterdam. https:\/\/doi.org\/10.1016\/b978-0-12-804281-6.00007-0.","DOI":"10.1016\/b978-0-12-804281-6.00007-0"},{"key":"3824_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jad.2021.06.020","volume":"293","author":"SY Zhang","year":"2021","unstructured":"Zhang SY, Qiu SW, Pan MR, Zhao MJ, Zhao RJ, Liu L, et al. Adult ADHD, executive function, depressive\/anxiety symptoms, and quality of life: a serial two-mediator model. J Affect Disord. 2021;293:97\u2013108. https:\/\/doi.org\/10.1016\/j.jad.2021.06.020","journal-title":"J Affect Disord"},{"key":"3824_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/schbul\/sbq077","volume":"38","author":"AW Tolman","year":"2012","unstructured":"Tolman AW, Kurtz MM. Neurocognitive predictors of objective and subjective quality of life in individuals with schizophrenia: a meta-analytic investigation. Schizophr Bull. 2012;38:304\u201315. https:\/\/doi.org\/10.1093\/schbul\/sbq077","journal-title":"Schizophr Bull"},{"key":"3824_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.04.009","volume":"27","author":"RA Lawson","year":"2016","unstructured":"Lawson RA, Yarnall AJ, Duncan GW, Breen DP, Khoo TK, Williams-Gray CH, et al. Cognitive decline and quality of life in incident Parkinson\u2019s disease: the role of attention. Park Relat Disord. 2016;27:47\u201353. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.04.009","journal-title":"Park Relat Disord"},{"key":"3824_CR29","doi-asserted-by":"publisher","unstructured":"Luerssen A, Ayduk O. Executive functions promote well-being: outcomes and mediators. In: Robinson M and Eid M (eds) The Happy Mind: Cognitive Contributions to Well-Being. 2017. Springer Cham. https:\/\/doi.org\/10.1007\/978-3-319-58763-9_4.","DOI":"10.1007\/978-3-319-58763-9_4"},{"key":"3824_CR30","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/s0021-9258(18)64731-3","volume":"233","author":"J Axelrod","year":"1958","unstructured":"Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem. 1958;233:702\u20135. https:\/\/doi.org\/10.1016\/s0021-9258(18)64731-3","journal-title":"J Biol Chem"},{"key":"3824_CR31","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1089\/dna.1991.10.181","volume":"10","author":"K Lundstrom","year":"1991","unstructured":"Lundstrom K, Salminen M, Jalanko A, Savolainen R, Ulmanen I. Cloning and characterization of human placental catechol-methyltransferase cDNA. DNA Cell Biol. 1991;10:181\u20139. https:\/\/doi.org\/10.1089\/dna.1991.10.181","journal-title":"DNA Cell Biol"},{"key":"3824_CR32","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1021\/bi00013a008","volume":"34","author":"T Lotta","year":"1995","unstructured":"Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Mel\u00e9n K, Julkunen I, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34:4202\u201310. https:\/\/doi.org\/10.1021\/bi00013a008","journal-title":"Biochemistry"},{"key":"3824_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/bfb0036121","volume":"120","author":"JA Roth","year":"2005","unstructured":"Roth JA. Membrane-bound COMT: a reevaluation of its role in the O-mathylation of the catecholamine neurotransmitters. Rev Physiol, Biochem Pharmacol. 2005;120:1\u201329. https:\/\/doi.org\/10.1007\/bfb0036121","journal-title":"Rev Physiol, Biochem Pharmacol"},{"key":"3824_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.173909","volume":"896","author":"Y Su","year":"2021","unstructured":"Su Y, DePasquale M, Liao G, Buchler I, Zhang G, Byers S, et al. Membrane bound catechol-O-methytransferase is the dominant isoform for dopamine metabolism in PC12 cells and rat brain. Eur J Pharmacol. 2021;896:173909. https:\/\/doi.org\/10.1016\/j.ejphar.2021.173909","journal-title":"Eur J Pharmacol"},{"key":"3824_CR35","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1126\/science.1262110","volume":"348","author":"Consortium TGte","year":"2015","unstructured":"The GTEx Consortium. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348:648\u201360. https:\/\/doi.org\/10.1126\/science.1262110","journal-title":"Science"},{"key":"3824_CR36","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1086\/425589","volume":"75","author":"J Chen","year":"2004","unstructured":"Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in Catechol-O-Methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004;75:807\u201321. https:\/\/doi.org\/10.1086\/425589","journal-title":"Am J Hum Genet"},{"key":"3824_CR37","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1093\/cercor\/bhl032","volume":"17","author":"EM Tunbridge","year":"2007","unstructured":"Tunbridge EM, Weickert CS, Kleinman JE, Herman MM, Chen J, Kolachana BS, et al. Catechol-o-methyltransferase enzyme activity and protein expression in human prefrontal cortex across the postnatal lifespan. Cereb Cortex. 2007;17:1206\u201312. https:\/\/doi.org\/10.1093\/cercor\/bhl032","journal-title":"Cereb Cortex"},{"key":"3824_CR38","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/00008571-199606000-00007","volume":"6","author":"HM Lachman","year":"1996","unstructured":"Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6:243\u201350. https:\/\/doi.org\/10.1097\/00008571-199606000-00007","journal-title":"Pharmacogenetics"},{"key":"3824_CR39","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.biopsych.2019.05.014","volume":"86","author":"EM Tunbridge","year":"2019","unstructured":"Tunbridge EM, Narajos M, Harrison CH, Beresford C, Cipriani A, Harrison PJ. Which dopamine polymorphisms are functional? Systematic review and meta-analysis of COMT, DAT, DBH, DDC, DRD1\u20135, MAOA, MAOB, TH, VMAT1, and VMAT2. Biol Psychiatry. 2019;86:608\u201320. https:\/\/doi.org\/10.1016\/j.biopsych.2019.05.014","journal-title":"Biol Psychiatry"},{"key":"3824_CR40","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1126\/science.1131262","volume":"314","author":"AG Nackley","year":"2006","unstructured":"Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, et al. Human Catechol-O-Methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science. 2006;314:1930\u20133. https:\/\/doi.org\/10.1126\/science.1131262","journal-title":"Science"},{"key":"3824_CR41","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/s41593-018-0197-y","volume":"21","author":"AE Jaffe","year":"2018","unstructured":"Jaffe AE, Straub RE, Shin JH, Tao R, Gao Y, Collado-Torres L, et al. Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis. Nat Neurosci. 2018;21:1117\u201325. https:\/\/doi.org\/10.1038\/s41593-018-0197-y","journal-title":"Nat Neurosci"},{"key":"3824_CR42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/b978-0-12-381326-8.00002-8","volume":"95","author":"EM Tunbridge","year":"2010","unstructured":"Tunbridge EM. The catechol-O-methyltransferase gene its regulation and polymorphisms. Int Rev Neurobiol. 2010;95:7\u201327. https:\/\/doi.org\/10.1016\/b978-0-12-381326-8.00002-8","journal-title":"Int Rev Neurobiol"},{"key":"3824_CR43","doi-asserted-by":"publisher","first-page":"7680","DOI":"10.1007\/s12035-024-04070-2","volume":"61","author":"O Tonk","year":"2024","unstructured":"Tonk O, Tokgun PE, Y\u0131lmaz \u00d6S, Tokgun O, Inci K, \u00c7elikkaya B, et al. An in vitro study for the role of schizophrenia-related potential miRNAs in the regulation of COMT gene. Mol Neurobiol. 2024;61:7680\u201390. https:\/\/doi.org\/10.1007\/s12035-024-04070-2","journal-title":"Mol Neurobiol"},{"key":"3824_CR44","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40263-021-00888-9","volume":"36","author":"M Fabbri","year":"2022","unstructured":"Fabbri M, Ferreira JJ, Rascol O. COMT inhibitors in the management of Parkinson\u2019s disease. CNS Drugs. 2022;36:261\u201382. https:\/\/doi.org\/10.1007\/s40263-021-00888-9","journal-title":"CNS Drugs"},{"key":"3824_CR45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"PA LeWitt","year":"2015","unstructured":"LeWitt PA. Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30:64\u201372. https:\/\/doi.org\/10.1002\/mds.26082","journal-title":"Mov Disord"},{"key":"3824_CR46","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40120-024-00629-2","volume":"13","author":"PT M\u00e4nnist\u00f6","year":"2024","unstructured":"M\u00e4nnist\u00f6 PT, Ker\u00e4nen T, Reinikainen KJ, Hanttu A, Pollesello P. The catechol O-methyltransferase inhibitor entacapone in the treatment of Parkinson\u2019s disease: personal reflections on a first-in-class drug development programme 40 years on. Neurol Ther. 2024;13:1039\u201354. https:\/\/doi.org\/10.1007\/s40120-024-00629-2","journal-title":"Neurol Ther"},{"key":"3824_CR47","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/syn.10034","volume":"43","author":"R Ceravolo","year":"2002","unstructured":"Ceravolo R, Piccini P, Bailey DL, Jorga KM, Bryson H, Brooks DJ. 18F\u2010dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson\u2019s disease. Synapse. 2002;43:201\u20137. https:\/\/doi.org\/10.1002\/syn.10034","journal-title":"Synapse"},{"key":"3824_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.707723","volume":"12","author":"Z Song","year":"2021","unstructured":"Song Z, Zhang J, Xue T, Yang Y, Wu D, Chen Z, et al. Different catechol-O-methyl transferase inhibitors in Parkinson\u2019s disease: a bayesian network meta-analysis. Front Neurol. 2021;12:707723 https:\/\/doi.org\/10.3389\/fneur.2021.707723","journal-title":"Front Neurol"},{"key":"3824_CR49","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1021\/acsptsci.4c00124","volume":"7","author":"M Pinto","year":"2024","unstructured":"Pinto M, Silva TB, Sard\u00e3o VA, Sim\u00f5es R, Albuquerque B, Oliveira PJ, et al. Cellular and mitochondrial toxicity of tolcapone, entacapone, and new nitrocatechol derivatives. ACS Pharmacol Transl Sci. 2024;7:1637\u201349. https:\/\/doi.org\/10.1021\/acsptsci.4c00124","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3824_CR50","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00228-020-03081-x","volume":"77","author":"CA Artusi","year":"2021","unstructured":"Artusi CA, Sarro L, Imbalzano G, Fabbri M, Lopiano L. Safety and efficacy of tolcapone in Parkinson\u2019s disease: systematic review. Eur J Clin Pharmacol. 2021;77:817\u201329. https:\/\/doi.org\/10.1007\/s00228-020-03081-x","journal-title":"Eur J Clin Pharmacol"},{"key":"3824_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/b978-0-12-381326-8.00007-7","volume":"95","author":"K Haasio","year":"2010","unstructured":"Haasio K. Toxicology and safety of comt inhibitors. Int Rev Neurobiol. 2010;95:163\u201389. https:\/\/doi.org\/10.1016\/b978-0-12-381326-8.00007-7","journal-title":"Int Rev Neurobiol"},{"key":"3824_CR52","doi-asserted-by":"publisher","first-page":"44005","DOI":"10.1021\/acsomega.4c06190","volume":"9","author":"S Bindra","year":"2024","unstructured":"Bindra S, Datta A, Yasin HKA, Thomas RR, Verma S, Patel A, et al. Recent progress in synthetic and natural catechol-O-methyltransferase inhibitors for neurological disorders. ACS Omega. 2024;9:44005\u201318. https:\/\/doi.org\/10.1021\/acsomega.4c06190","journal-title":"ACS Omega"},{"key":"3824_CR53","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1177\/0269881112454228","volume":"26","author":"L Laatikainen","year":"2012","unstructured":"Laatikainen L, Sharp T, Bannerman D, Harrison P, Tunbridge E. Modulation of hippocampal dopamine metabolism and hippocampal-dependent cognitive function by catechol-O-methyltransferase inhibition. J Psychopharmacol. 2012;26:1561\u20138. https:\/\/doi.org\/10.1177\/0269881112454228","journal-title":"J Psychopharmacol"},{"key":"3824_CR54","doi-asserted-by":"publisher","first-page":"e61839","DOI":"10.1371\/journal.pone.0061839","volume":"8","author":"LM Laatikainen","year":"2013","unstructured":"Laatikainen LM, Sharp T, Harrison PJ, Tunbridge EM. Sexually dimorphic effects of catechol-O-methyltransferase (COMT) inhibition on dopamine metabolism in multiple brain regions. PLoS ONE. 2013;8:e61839 https:\/\/doi.org\/10.1371\/journal.pone.0061839","journal-title":"PLoS ONE"},{"key":"3824_CR55","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1038\/npp.2016.119","volume":"41","author":"C Barkus","year":"2016","unstructured":"Barkus C, Korn C, Stumpenhorst K, Laatikainen LM, Ballard D, Lee S, et al. Genotype-dependent effects of COMT inhibition on cognitive function in a highly specific, novel mouse model of altered COMT activity. Neuropsychopharmacology. 2016;41:3060\u20139. https:\/\/doi.org\/10.1038\/npp.2016.119","journal-title":"Neuropsychopharmacology"},{"key":"3824_CR56","doi-asserted-by":"publisher","first-page":"9991","DOI":"10.1073\/pnas.95.17.9991","volume":"95","author":"JA Gogos","year":"1998","unstructured":"Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci. 1998;95:9991\u20136. https:\/\/doi.org\/10.1073\/pnas.95.17.9991","journal-title":"Proc Natl Acad Sci"},{"key":"3824_CR57","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00213-008-1342-1","volume":"202","author":"CC Lapish","year":"2009","unstructured":"Lapish CC, Ahn S, Evangelista LM, So K, Seamans JK, Phillips AG. Tolcapone enhances food-evoked dopamine efflux and executive memory processes mediated by the rat prefrontal cortex. Psychopharmacology. 2009;202:521\u201330. https:\/\/doi.org\/10.1007\/s00213-008-1342-1","journal-title":"Psychopharmacology"},{"key":"3824_CR58","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.1523\/jneurosci.1124-04.2004","volume":"24","author":"EM Tunbridge","year":"2004","unstructured":"Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ. Catechol-O-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci. 2004;24:5331\u20135. https:\/\/doi.org\/10.1523\/jneurosci.1124-04.2004","journal-title":"J Neurosci"},{"key":"3824_CR59","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/s1353-8020(02)00016-0","volume":"9","author":"A Napolitano","year":"2003","unstructured":"Napolitano A, Bellini G, Borroni E, Z\u00fcrcher G, Bonuccelli U. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats. Park Relat Disord. 2003;9:145\u201350. https:\/\/doi.org\/10.1016\/s1353-8020(02)00016-0","journal-title":"Park Relat Disord"},{"key":"3824_CR60","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1111\/j.1471-4159.2010.06889.x","volume":"114","author":"M K\u00e4enm\u00e4ki","year":"2010","unstructured":"K\u00e4enm\u00e4ki M, Tammim\u00e4ki A, My\u00f6h\u00e4nen T, Pakarinen K, Amberg C, Karayiorgou M, et al. Quantitative role of COMT in dopamine clearance in the prefrontal cortex of freely moving mice. J Neurochem. 2010;114:1745\u201355. https:\/\/doi.org\/10.1111\/j.1471-4159.2010.06889.x","journal-title":"J Neurochem"},{"key":"3824_CR61","doi-asserted-by":"publisher","first-page":"10196","DOI":"10.1523\/jneurosci.0665-07.2007","volume":"27","author":"L Yavich","year":"2007","unstructured":"Yavich L, Forsberg MM, Karayiorgou M, Gogos JA, M\u00e4nnist\u00f6 PT. Site-specific role of catechol- O -methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum. J Neurosci. 2007;27:10196\u2013209. https:\/\/doi.org\/10.1523\/jneurosci.0665-07.2007","journal-title":"J Neurosci"},{"key":"3824_CR62","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/mp.2008.19","volume":"13","author":"M Slifstein","year":"2008","unstructured":"Slifstein M, Kolachana B, Simpson EH, Tabares P, Cheng B, Duvall M, et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol Psychiatr. 2008;13:821\u20137. https:\/\/doi.org\/10.1038\/mp.2008.19","journal-title":"Mol Psychiatr"},{"key":"3824_CR63","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1046\/j.1471-4159.1994.63030972.x","volume":"63","author":"F Karoum","year":"1994","unstructured":"Karoum F, Chrapusta SJ, Egan MF. 3\u2010methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem. 1994;63:972\u20139. https:\/\/doi.org\/10.1046\/j.1471-4159.1994.63030972.x","journal-title":"J Neurochem"},{"key":"3824_CR64","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/s0031-6997(25)06859-0","volume":"37","author":"IJ Kopin","year":"1985","unstructured":"Kopin IJ. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev. 1985;37:333\u201364. https:\/\/doi.org\/10.1016\/s0031-6997(25)06859-0","journal-title":"Pharmacol Rev"},{"key":"3824_CR65","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1001\/jamapsychiatry.2014.2414","volume":"72","author":"M Slifstein","year":"2015","unstructured":"Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. Jama Psychiat. 2015;72:316\u201324. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.2414","journal-title":"Jama Psychiat"},{"key":"3824_CR66","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/hbm.22006","volume":"34","author":"JH Ko","year":"2013","unstructured":"Ko JH, Antonelli F, Monchi O, Ray N, Rusjan P, Houle S, et al. Prefrontal dopaminergic receptor abnormalities and executive functions in Parkinson\u2019s disease. Hum Brain Mapp. 2013;34:1591\u2013604. https:\/\/doi.org\/10.1002\/hbm.22006","journal-title":"Hum Brain Mapp"},{"key":"3824_CR67","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00213-015-4151-3","volume":"233","author":"EN Holly","year":"2016","unstructured":"Holly EN, Miczek KA. Ventral tegmental area dopamine revisited: effects of acute and repeated stress. Psychopharmacology. 2016;233:163\u201386. https:\/\/doi.org\/10.1007\/s00213-015-4151-3","journal-title":"Psychopharmacology"},{"key":"3824_CR68","doi-asserted-by":"publisher","first-page":"i6","DOI":"10.1093\/cercor\/bhm033","volume":"17","author":"AFT Arnsten","year":"2007","unstructured":"Arnsten AFT. Catecholamine and second messenger influences on prefrontal cortical networks of \u201cRepresentational Knowledge\u201d: a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex. 2007;17:i6\u2013i15. https:\/\/doi.org\/10.1093\/cercor\/bhm033","journal-title":"Cereb Cortex"},{"key":"3824_CR69","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.neuropharm.2013.10.014","volume":"77","author":"MJ Bonif\u00e1cio","year":"2014","unstructured":"Bonif\u00e1cio MJ, Sutcliffe JS, Torr\u00e3o L, Wright LC, Soares-da-Silva P. Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor. Neuropharmacology. 2014;77:334\u201341. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.10.014","journal-title":"Neuropharmacology"},{"key":"3824_CR70","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.biopsych.2011.03.028","volume":"69","author":"R Cools","year":"2011","unstructured":"Cools R, D\u2019Esposito M. Inverted-U\u2013shaped dopamine actions on human working memory and cognitive control. Biol Psychiatry. 2011;69:e113\u2013e125. https:\/\/doi.org\/10.1016\/j.biopsych.2011.03.028","journal-title":"Biol Psychiatry"},{"key":"3824_CR71","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fnins.2013.00062","volume":"7","author":"SB Floresco","year":"2013","unstructured":"Floresco SB. Prefrontal dopamine and behavioral flexibility: shifting from an \u201cinverted-U\u201d toward a family of functions. Front Neurosci. 2013;7:62 https:\/\/doi.org\/10.3389\/fnins.2013.00062","journal-title":"Front Neurosci"},{"key":"3824_CR72","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.biopsych.2008.05.015","volume":"64","author":"D Durstewitz","year":"2008","unstructured":"Durstewitz D, Seamans JK. The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-O-methyltransferase genotypes and schizophrenia. Biol Psychiatry. 2008;64:739\u201349. https:\/\/doi.org\/10.1016\/j.biopsych.2008.05.015","journal-title":"Biol Psychiatry"},{"key":"3824_CR73","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1037\/bne0000512","volume":"136","author":"MA Weber","year":"2022","unstructured":"Weber MA, Conlon MM, Stutt HR, Wendt L, Eyck PT, Narayanan NS. Quantifying the Inverted U: A meta-analysis of prefrontal dopamine, D1 receptors, and working memory. Behav Neurosci. 2022;136:207\u201318. https:\/\/doi.org\/10.1037\/bne0000512","journal-title":"Behav Neurosci"},{"key":"3824_CR74","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1098\/rstb.2007.2098","volume":"362","author":"JD Cohen","year":"2007","unstructured":"Cohen JD, McClure SM, Yu AJ. Should I stay or should I go? How the human brain manages the trade-off between exploitation and exploration. Philos Trans R Soc B: Biol Sci. 2007;362:933\u201342. https:\/\/doi.org\/10.1098\/rstb.2007.2098","journal-title":"Philos Trans R Soc B: Biol Sci"},{"key":"3824_CR75","doi-asserted-by":"publisher","unstructured":"Robbins TW. Optimizing the executive: neurochemical modulation of the fronto-executive \u201cToolbox\u201d. Principles of Frontal Lobe Function. Oxford Academic. New York. Published online 2013: https:\/\/doi.org\/10.1093\/med\/9780199837755.003.0006.","DOI":"10.1093\/med\/9780199837755.003.0006"},{"key":"3824_CR76","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1017\/s1092852924000130","volume":"29","author":"E Kings","year":"2024","unstructured":"Kings E, Ioannidis K, Grant JE, Chamberlain SR. A systematic review of the cognitive effects of the COMT inhibitor, tolcapone, in adult humans. CNS Spectr. 2024;29:166\u201375. https:\/\/doi.org\/10.1017\/s1092852924000130","journal-title":"CNS Spectr"},{"key":"3824_CR77","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/bf01285556","volume":"104","author":"M Gasparini","year":"1997","unstructured":"Gasparini M, Fabrizio E, Bonifati V, Meco G. Cognitive improvement during tolcapone treatment in Parkinson\u2019s disease. J Neural Transmission. 1997;104:887\u201394. https:\/\/doi.org\/10.1007\/bf01285556","journal-title":"J Neural Transmission"},{"key":"3824_CR78","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.biopsych.2011.12.023","volume":"71","author":"SM Farrell","year":"2012","unstructured":"Farrell SM, Tunbridge EM, Braeutigam S, Harrison PJ. COMT Val158Met genotype determines the direction of cognitive effects produced by catechol-O-methyltransferase inhibition. Biol Psychiat. 2012;71:538\u201344. https:\/\/doi.org\/10.1016\/j.biopsych.2011.12.023","journal-title":"Biol Psychiat"},{"key":"3824_CR79","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1038\/npp.2008.82","volume":"33","author":"SG Giakoumaki","year":"2008","unstructured":"Giakoumaki SG, Roussos P, Bitsios P. Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacol. 2008;33:3058\u201368. https:\/\/doi.org\/10.1038\/npp.2008.82","journal-title":"Neuropsychopharmacol"},{"key":"3824_CR80","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.biopsych.2009.07.008","volume":"66","author":"P Roussos","year":"2009","unstructured":"Roussos P, Giakoumaki SG, Bitsios P. Tolcapone effects on gating, working memory, and mood interact with the synonymous catechol-O-methyltransferase rs4818C\/G polymorphism. Biol Psychiat. 2009;66:997\u20131004. https:\/\/doi.org\/10.1016\/j.biopsych.2009.07.008","journal-title":"Biol Psychiat"},{"key":"3824_CR81","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/sj.npp.1301227","volume":"32","author":"JA Apud","year":"2007","unstructured":"Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, et al. Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology. 2007;32:1011\u201320. https:\/\/doi.org\/10.1038\/sj.npp.1301227","journal-title":"Neuropsychopharmacology"},{"key":"3824_CR82","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1093\/bioinformatics\/btv402","volume":"31","author":"MJ Machiela","year":"2015","unstructured":"Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31:3555\u20137. https:\/\/doi.org\/10.1093\/bioinformatics\/btv402","journal-title":"Bioinformatics"},{"key":"3824_CR83","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1162\/jocn_a_01518","volume":"32","author":"DJ Furman","year":"2020","unstructured":"Furman DJ, White RL, Naskolnakorn J, Ye J, Kayser A, D\u2019Esposito M. Effects of dopaminergic drugs on cognitive control processes vary by genotype. J Cognitive Neurosci. 2020;32:804\u201321. https:\/\/doi.org\/10.1162\/jocn_a_01518","journal-title":"J Cognitive Neurosci"},{"key":"3824_CR84","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3389\/fphar.2019.00404","volume":"10","author":"SA Torrisi","year":"2019","unstructured":"Torrisi SA, Leggio GM, Drago F, Salomone S. Therapeutic challenges of post-traumatic stress disorder: focus on the dopaminergic system. Front Pharmacol. 2019;10:404 https:\/\/doi.org\/10.3389\/fphar.2019.00404","journal-title":"Front Pharmacol"},{"key":"3824_CR85","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/schbul\/sby076","volume":"45","author":"N Rao","year":"2018","unstructured":"Rao N, Northoff G, Tagore A, Rusjan P, Kenk M, Wilson A, et al. Impaired prefrontal cortical dopamine release in schizophrenia during a cognitive task: a [11C]FLB 457 positron emission tomography study. Schizophrenia Bull. 2018;45:670\u20139. https:\/\/doi.org\/10.1093\/schbul\/sby076","journal-title":"Schizophrenia Bull"},{"key":"3824_CR86","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.biopsych.2022.05.009","volume":"92","author":"WG Frankle","year":"2022","unstructured":"Frankle WG, Himes M, Mason NS, Mathis CA, Narendran R. Prefrontal and striatal dopamine release are inversely correlated in schizophrenia. Biol Psychiat. 2022;92:791\u20139. https:\/\/doi.org\/10.1016\/j.biopsych.2022.05.009","journal-title":"Biol Psychiat"},{"key":"3824_CR87","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.schres.2010.02.423","volume":"117","author":"S Giakoumaki","year":"2010","unstructured":"Giakoumaki S, Tsapakis EM, Roussos P, Chrysoulaki A, Kopsahili I, Bitsios P. Single dose tolcapone administration improves working memory and sensorimotor gating in psychotic patients. Schizophr Res. 2010;117:266 https:\/\/doi.org\/10.1016\/j.schres.2010.02.423","journal-title":"Schizophr Res"},{"key":"3824_CR88","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41398-021-01512-6","volume":"11","author":"AJ Westphal","year":"2021","unstructured":"Westphal AJ, Ballard ME, Rodriguez N, Vega TA, D\u2019Esposito M, Kayser AS. Working memory, cortical dopamine tone, and frontoparietal brain recruitment in post-traumatic stress disorder: a randomized controlled trial. Transl Psychiat. 2021;11:389 https:\/\/doi.org\/10.1038\/s41398-021-01512-6","journal-title":"Transl Psychiat"},{"key":"3824_CR89","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40263-013-0082-x","volume":"27","author":"SC Magalona","year":"2013","unstructured":"Magalona SC, Rasetti R, Chen J, Chen Q, Gold I, Decot H, et al. Effect of tolcapone on brain activity during a variable attentional control task: a double-blind, placebo-controlled, counter-balanced trial in healthy volunteers. CNS Drugs. 2013;27:663\u201373. https:\/\/doi.org\/10.1007\/s40263-013-0082-x","journal-title":"CNS Drugs"},{"key":"3824_CR90","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyx074","volume":"20","author":"SG Bhakta","year":"2017","unstructured":"Bhakta SG, Light GA, Talledo JA, Balvaneda B, Hughes E, Alvarez A, et al. Tolcapone-enhanced neurocognition in healthy adults: neural basis and predictors. Int J Neuropsychoph. 2017;20:pyx074 https:\/\/doi.org\/10.1093\/ijnp\/pyx074","journal-title":"Int J Neuropsychoph"},{"key":"3824_CR91","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1007\/s00213-020-05566-0","volume":"237","author":"S Byers","year":"2020","unstructured":"Byers S, Buchler IP, DePasquale M, Rowley HL, Kulkarni RS, Pinder L, et al. Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility. Psychopharmacology. 2020;237:2695\u2013707. https:\/\/doi.org\/10.1007\/s00213-020-05566-0","journal-title":"Psychopharmacology"},{"key":"3824_CR92","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/fbp.0000000000000208","volume":"27","author":"ER Detrait","year":"2016","unstructured":"Detrait ER, Carr GV, Weinberger DR, Lamberty Y. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice. Behav Pharmacol. 2016;27:415\u201321. https:\/\/doi.org\/10.1097\/fbp.0000000000000208","journal-title":"Behav Pharmacol"},{"key":"3824_CR93","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/npp.2014.29","volume":"39","author":"V Risbrough","year":"2014","unstructured":"Risbrough V, Ji B, Hauger R, Zhou X. Generation and characterization of humanized mice carrying COMT158 Met\/Val alleles. Neuropsychopharmacology. 2014;39:1823\u201332. https:\/\/doi.org\/10.1038\/npp.2014.29","journal-title":"Neuropsychopharmacology"},{"key":"3824_CR94","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.bbr.2011.12.014","volume":"228","author":"L Desbonnet","year":"2012","unstructured":"Desbonnet L, Tighe O, Karayiorgou M, Gogos JA, Waddington JL, O\u2019Tuathaigh CMP. Physiological and behavioural responsivity to stress and anxiogenic stimuli in COMT-deficient mice. Behav Brain Res. 2012;228:351\u20138. https:\/\/doi.org\/10.1016\/j.bbr.2011.12.014","journal-title":"Behav Brain Res"},{"key":"3824_CR95","doi-asserted-by":"publisher","first-page":"8709","DOI":"10.1523\/jneurosci.2077-08.2008","volume":"28","author":"F Papaleo","year":"2008","unstructured":"Papaleo F, Crawley JN, Song J, Lipska BK, Pickel J, Weinberger DR, et al. Genetic dissection of the role of catechol- O -methyltransferase in cognition and stress reactivity in mice. J Neurosci. 2008;28:8709\u201323. https:\/\/doi.org\/10.1523\/jneurosci.2077-08.2008","journal-title":"J Neurosci"},{"key":"3824_CR96","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.brainresbull.2011.11.012","volume":"88","author":"AV Witte","year":"2012","unstructured":"Witte AV, Fl\u00f6el A. Effects of COMT polymorphisms on brain function and behavior in health and disease. Brain Res Bull. 2012;88:418\u201328. https:\/\/doi.org\/10.1016\/j.brainresbull.2011.11.012","journal-title":"Brain Res Bull"},{"key":"3824_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.136243","volume":"764","author":"J Chung","year":"2021","unstructured":"Chung J, Ushakova A, Doitsidou M, Tzoulis C, Tysnes OB, Dalen I, et al. The impact of common genetic variants in cognitive decline in the first seven years of Parkinson\u2019s disease: a longitudinal observational study. Neurosci Lett. 2021;764:136243 https:\/\/doi.org\/10.1016\/j.neulet.2021.136243","journal-title":"Neurosci Lett"},{"key":"3824_CR98","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rpsm.2021.11.002","volume":"15","author":"E Rodr\u00edguez-Toscano","year":"2022","unstructured":"Rodr\u00edguez-Toscano E, Mart\u00ednez K, Fraguas D, Janssen J, Pina-Camacho L, Arias B, et al. Prefrontal abnormalities, executive dysfunction and symptoms severity are modulated by COMT Val158Met polymorphism in first episode psychosis. Rev Psiquiatr y Salud Ment. 2022;15:74\u201387. https:\/\/doi.org\/10.1016\/j.rpsm.2021.11.002","journal-title":"Rev Psiquiatr y Salud Ment"},{"key":"3824_CR99","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/mp.2015.16","volume":"20","author":"MS Farrell","year":"2015","unstructured":"Farrell MS, Werge T, Sklar P, Owen MJ, Ophoff RA, O'Donovan MC, et al. Evaluating historical candidate genes for schizophrenia. Mol Psychiatry. 2015;20:555\u201362. https:\/\/doi.org\/10.1038\/mp.2015.16","journal-title":"Mol Psychiatry"},{"key":"3824_CR100","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1038\/s41380-023-02293-8","volume":"28","author":"MJ Owen","year":"2023","unstructured":"Owen MJ, Legge SE, Rees E, Walters JTR, O\u2019Donovan MC. Genomic findings in schizophrenia and their implications. Mol Psychiatry. 2023;28:3638\u201347. https:\/\/doi.org\/10.1038\/s41380-023-02293-8","journal-title":"Mol Psychiatry"},{"key":"3824_CR101","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1038\/sj.npp.1300787","volume":"30","author":"MB Stein","year":"2005","unstructured":"Stein MB, Fallin MD, Schork NJ, Gelernter J. COMT polymorphisms and anxiety-related personality traits. Neuropsychopharmacology. 2005;30:2092\u2013102. https:\/\/doi.org\/10.1038\/sj.npp.1300787","journal-title":"Neuropsychopharmacology"},{"key":"3824_CR102","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00041444-200506000-00007","volume":"15","author":"CA Olsson","year":"2005","unstructured":"Olsson CA, Anney RJL, Lotfi-Miri M, Byrnes GB, Williamson R, Patton GC. Association between the COMT Val158Met polymorphism and propensity to anxiety in an Australian population-based longitudinal study of adolescent health. Psychiatr Genet. 2005;15:109\u201315. https:\/\/doi.org\/10.1097\/00041444-200506000-00007","journal-title":"Psychiatr Genet"},{"key":"3824_CR103","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1017\/s1461145711001763","volume":"15","author":"D Armbruster","year":"2012","unstructured":"Armbruster D, Mueller A, Strobel A, Lesch KP, Brocke B, Kirschbaum C. Children under stress \u2013 COMT genotype and stressful life events predict cortisol increase in an acute social stress paradigm. Int J Neuropsychopharmacol. 2012;15:1229\u201339. https:\/\/doi.org\/10.1017\/s1461145711001763","journal-title":"Int J Neuropsychopharmacol"},{"key":"3824_CR104","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jpain.2013.10.004","volume":"15","author":"J Desmeules","year":"2014","unstructured":"Desmeules J, Chabert J, Rebsamen M, Rapiti E, Piguet V, Besson M, et al. Central pain sensitization, COMT Val158Met polymorphism, and emotional factors in fibromyalgia. J Pain. 2014;15:129\u201335. https:\/\/doi.org\/10.1016\/j.jpain.2013.10.004","journal-title":"J Pain"},{"key":"3824_CR105","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1126\/science.1078546","volume":"299","author":"JK Zubieta","year":"2003","unstructured":"Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, et al. COMT val158met genotype affects \u00b5-opioid neurotransmitter responses to a pain stressor. Science. 2003;299:1240\u20133. https:\/\/doi.org\/10.1126\/science.1078546","journal-title":"Science"},{"key":"3824_CR106","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41588-024-01908-2","volume":"56","author":"E Friligkou","year":"2024","unstructured":"Friligkou E, L\u00f8khammer S, Cabrera-Mendoza B, Shen J, He J, Deiana G, et al. Gene discovery and biological insights into anxiety disorders from a large-scale multi-ancestry genome-wide association study. Nat Genet. 2024;56:2036\u201345. https:\/\/doi.org\/10.1038\/s41588-024-01908-2","journal-title":"Nat Genet"},{"key":"3824_CR107","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1097\/j.pain.0000000000002922","volume":"164","author":"K Zorina-Lichtenwalter","year":"2023","unstructured":"Zorina-Lichtenwalter K, Bango CI, Van Oudenhove L, \u010ceko M, Lindquist MA, Grotzinger AD, et al. Genetic risk shared across 24 chronic pain conditions: identification and characterization with genomic structural equation modeling. PAIN. 2023;164:2239\u201352. https:\/\/doi.org\/10.1097\/j.pain.0000000000002922","journal-title":"PAIN"},{"key":"3824_CR108","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ajmg.b.32078","volume":"159B","author":"ML Molendijk","year":"2012","unstructured":"Molendijk ML, Bus BA, Spinhoven P, Kaimatzoglou A, Oude Voshaar RC, Penninx BW, et al. A systematic review and meta\u2010analysis on the association between BDNF val66met and hippocampal volume\u2014A genuine effect or a winners curse? Am J Me\u0301d Genet Part B: Neuropsychiatr Genet. 2012;159B:731\u201340. https:\/\/doi.org\/10.1002\/ajmg.b.32078","journal-title":"Am J Me\u0301d Genet Part B: Neuropsychiatr Genet"},{"key":"3824_CR109","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ajmg.b.32556","volume":"177","author":"S Taylor","year":"2018","unstructured":"Taylor S. Association between COMT Val158Met and psychiatric disorders: a comprehensive meta\u2010analysis. Am J Me\u0301d Genet Part B: Neuropsychiatr Genet. 2018;177:199\u2013210. https:\/\/doi.org\/10.1002\/ajmg.b.32556","journal-title":"Am J Me\u0301d Genet Part B: Neuropsychiatr Genet"},{"key":"3824_CR110","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/npp.2013.24","volume":"38","author":"MC Wardle","year":"2013","unstructured":"Wardle MC, de Wit H, Penton-Voak I, Lewis G, Munaf\u00f2 MR. Lack of association between COMT and working memory in a population-based cohort of healthy young adults. Neuropsychopharmacology. 2013;38:1253\u201363. https:\/\/doi.org\/10.1038\/npp.2013.24","journal-title":"Neuropsychopharmacology"},{"key":"3824_CR111","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/mp.2016.244","volume":"22","author":"JW Trampush","year":"2017","unstructured":"Trampush JW, Yang ML, Yu J, Knowles E, Davies G, Liewald DC, et al. GWAS meta-analysis reveals novel loci and genetic correlates for general cognitive function: a report from the COGENT consortium. Mol Psychiatry. 2017;22:336\u201345. https:\/\/doi.org\/10.1038\/mp.2016.244","journal-title":"Mol Psychiatry"},{"key":"3824_CR112","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1038\/s41588-018-0152-6","volume":"50","author":"JE Savage","year":"2018","unstructured":"Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, de Leeuw CA, et al. Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nat Genet. 2018;50:912\u20139. https:\/\/doi.org\/10.1038\/s41588-018-0152-6","journal-title":"Nat Genet"},{"key":"3824_CR113","unstructured":"Apud J, Tong Y, Rasetti R, Vargas T, Das S, Weinberger DR, et al. Personal communication. Published online 2017."},{"key":"3824_CR114","doi-asserted-by":"publisher","first-page":"13393","DOI":"10.1523\/jneurosci.4041-07.2007","volume":"27","author":"HY Tan","year":"2007","unstructured":"Tan HY, Chen Q, Goldberg TE, Mattay VS, Meyer-Lindenberg A, Weinberger DR, et al. Catechol-O-methyltransferase Val158Met modulation of prefrontal\u2013parietal\u2013striatal brain systems during arithmetic and temporal transformations in working memory. J Neurosci. 2007;27:13393\u2013401. https:\/\/doi.org\/10.1523\/jneurosci.4041-07.2007","journal-title":"J Neurosci"},{"key":"3824_CR115","doi-asserted-by":"publisher","first-page":"9402","DOI":"10.1523\/jneurosci.1180-12.2012","volume":"32","author":"AS Kayser","year":"2012","unstructured":"Kayser AS, Allen DC, Navarro-Cebrian A, Mitchell JM, Fields HL. Dopamine, corticostriatal connectivity, and intertemporal choice. J Neurosci. 2012;32:9402\u20139. https:\/\/doi.org\/10.1523\/jneurosci.1180-12.2012","journal-title":"J Neurosci"},{"key":"3824_CR116","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.euroneuro.2013.07.008","volume":"23","author":"JE Grant","year":"2013","unstructured":"Grant JE, Odlaug BL, Chamberlain SR, Hampshire A, Schreiber LRN, Kim SW. A proof of concept study of tolcapone for pathological gambling: relationships with COMT genotype and brain activation. Eur Neuropsychopharmacol. 2013;23:1587\u201396. https:\/\/doi.org\/10.1016\/j.euroneuro.2013.07.008","journal-title":"Eur Neuropsychopharmacol"},{"key":"3824_CR117","doi-asserted-by":"publisher","first-page":"ENEURO.0461-19.","DOI":"10.1523\/eneuro.0461-19.2020","volume":"7","author":"J Peters","year":"2020","unstructured":"Peters J, Vega T, Weinstein D, Mitchell J, Kayser A. Dopamine and risky decision-making in gambling disorder. eNeuro. 2020;7:ENEURO.0461-19.2020 https:\/\/doi.org\/10.1523\/eneuro.0461-19.2020","journal-title":"eNeuro"},{"key":"3824_CR118","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1038\/s41386-022-01335-z","volume":"47","author":"JP Schacht","year":"2022","unstructured":"Schacht JP, Im Y, Hoffman M, Voronin KE, Book SW, Anton RF. Effects of pharmacological and genetic regulation of COMT activity in alcohol use disorder: a randomized, placebo-controlled trial of tolcapone. Neuropsychopharmacol. 2022;47:1953\u201360. https:\/\/doi.org\/10.1038\/s41386-022-01335-z","journal-title":"Neuropsychopharmacol"},{"key":"3824_CR119","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1007\/s00213-020-05599-5","volume":"237","author":"AR Coker","year":"2020","unstructured":"Coker AR, Weinstein DN, Vega TA, Miller CS, Kayser AS, Mitchell JM. The catechol-O-methyltransferase inhibitor tolcapone modulates alcohol consumption and impulsive choice in alcohol use disorder. Psychopharmacology. 2020;237:3139\u201348. https:\/\/doi.org\/10.1007\/s00213-020-05599-5","journal-title":"Psychopharmacology"},{"key":"3824_CR120","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.nicl.2016.12.022","volume":"13","author":"AS Kayser","year":"2017","unstructured":"Kayser AS, Vega T, Weinstein D, Peters J, Mitchell JM. Right inferior frontal cortex activity correlates with tolcapone responsivity in problem and pathological gamblers. NeuroImage Clin. 2017;13:339\u201348. https:\/\/doi.org\/10.1016\/j.nicl.2016.12.022","journal-title":"NeuroImage Clin"},{"key":"3824_CR121","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1007\/s00213-018-4971-z","volume":"235","author":"JM Mitchell","year":"2018","unstructured":"Mitchell JM, Weinstein D, Vega T, Kayser AS. Dopamine, time perception, and future time perspective. Psychopharmacology. 2018;235:2783\u201393. https:\/\/doi.org\/10.1007\/s00213-018-4971-z","journal-title":"Psychopharmacology"},{"key":"3824_CR122","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1111\/acer.12515","volume":"38","author":"AM McCane","year":"2014","unstructured":"McCane AM, Czachowski CL, Lapish CC. Tolcapone suppresses ethanol intake in alcohol\u2010preferring rats performing a novel cued access protocol. Alcohol: Clin Exp Res. 2014;38:2468\u201378. https:\/\/doi.org\/10.1111\/acer.12515","journal-title":"Alcohol: Clin Exp Res"},{"key":"3824_CR123","doi-asserted-by":"publisher","DOI":"10.1523\/eneuro.0326-18.2018","volume":"5","author":"AM McCane","year":"2018","unstructured":"McCane AM, Ahn S, Rubchinsky LL, Janetsian-Fritz SS, Linsenbardt DN, Czachowski CL, et al. COMT inhibition alters cue-evoked oscillatory dynamics during alcohol drinking in the rat. eNeuro. 2018;5:ENEURO.0326-18.2018 https:\/\/doi.org\/10.1523\/eneuro.0326-18.2018","journal-title":"eNeuro"},{"key":"3824_CR124","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.alcohol.2017.08.007","volume":"67","author":"AM McCane","year":"2018","unstructured":"McCane AM, DeLory MJ, Timm MM, Janetsian-Fritz SS, Lapish CC, Czachowski CL. Differential COMT expression and behavioral effects of COMT inhibition in male and female Wistar and alcohol preferring rats. Alcohol. 2018;67:15\u201322. https:\/\/doi.org\/10.1016\/j.alcohol.2017.08.007","journal-title":"Alcohol"},{"key":"3824_CR125","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1101\/lm.032094.113","volume":"21","author":"EH Simpson","year":"2014","unstructured":"Simpson EH, Morud J, Winiger V, Biezonski D, Zhu JP, Bach ME, et al. Genetic variation in COMT activity impacts learning and dopamine release capacity in the striatum. Learn Mem. 2014;21:205\u201314. https:\/\/doi.org\/10.1101\/lm.032094.113","journal-title":"Learn Mem"},{"key":"3824_CR126","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/s41386-022-01291-8","volume":"47","author":"V Scholz","year":"2022","unstructured":"Scholz V, Hook RW, Kandroodi MR, Algermissen J, Ioannidis K, Christmas D, et al. Cortical dopamine reduces the impact of motivational biases governing automated behaviour. Neuropsychopharmacology. 2022;47:1503\u201312. https:\/\/doi.org\/10.1038\/s41386-022-01291-8","journal-title":"Neuropsychopharmacology"},{"key":"3824_CR127","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/yic.0000000000000368","volume":"36","author":"JE Grant","year":"2021","unstructured":"Grant JE, Hook R, Valle S, Chesivoir E, Chamberlain SR. Tolcapone in obsessive compulsive disorder: a randomized double-blind placebo-controlled crossover trial. Int Clin Psychopharmacol. 2021;36:225\u20139. https:\/\/doi.org\/10.1097\/yic.0000000000000368","journal-title":"Int Clin Psychopharmacol"},{"key":"3824_CR128","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.cub.2015.01.071","volume":"25","author":"I S\u00e1ez","year":"2015","unstructured":"S\u00e1ez I, Zhu L, Set E, Kayser A, Hsu M. Dopamine modulates egalitarian behavior in humans. Curr Biology. 2015;25:912\u20139. https:\/\/doi.org\/10.1016\/j.cub.2015.01.071","journal-title":"Curr Biology"},{"key":"3824_CR129","first-page":"329","volume":"19","author":"M Fava","year":"1999","unstructured":"Fava M, Rosenbaum JF, Kolsky AR, Alpert JE, Nierenberg AA, Spillmann M, et al. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. Journal of Clinical Pharmacology. Published online. 1999;19:329\u201335.","journal-title":"Journal of Clinical Pharmacology. Published online"},{"key":"3824_CR130","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1177\/02698811221089032","volume":"36","author":"MA Martens","year":"2022","unstructured":"Martens MA, Dalton N, Scaife J, Harmer CJ, Harrison PJ, Tunbridge EM. Catechol-O-methyltransferase activity does not influence emotional processing in men. J Psychopharmacol. 2022;36:768\u201375. https:\/\/doi.org\/10.1177\/02698811221089032","journal-title":"J Psychopharmacol"},{"key":"3824_CR131","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1523\/jneurosci.0774-07.2007","volume":"27","author":"CH Williams-Gray","year":"2007","unstructured":"Williams-Gray CH, Hampshire A, Robbins TW, Owen AM, Barker RA. Catechol O-methyltransferase val158met genotype influences frontoparietal activity during planning in patients with Parkinson\u2019s disease. J Neurosci. 2007;27:4832\u20138. https:\/\/doi.org\/10.1523\/jneurosci.0774-07.2007","journal-title":"J Neurosci"},{"key":"3824_CR132","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/mds.20118","volume":"19","author":"T Foltynie","year":"2004","unstructured":"Foltynie T, Goldberg TE, Lewis SG, Blackwell AD, Kolachana BS, Weinberger DR, et al. Planning ability in Parkinson\u2019s disease is influenced by the COMT val158met polymorphism. Mov Disord. 2004;19:885\u201391. https:\/\/doi.org\/10.1002\/mds.20118","journal-title":"Mov Disord"},{"key":"3824_CR133","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3233\/jad-191265","volume":"75","author":"R Fremont","year":"2020","unstructured":"Fremont R, Manoochehri M, Armstrong NM, Mattay VS, Apud JA, Tierney MC, et al. Tolcapone treatment for cognitive and behavioral symptoms in behavioral variant frontotemporal dementia: a placebo-controlled crossover study. J Alzheimer\u2019s Dis. 2020;75:1391\u2013403. https:\/\/doi.org\/10.3233\/jad-191265","journal-title":"J Alzheimer\u2019s Dis"},{"key":"3824_CR134","doi-asserted-by":"publisher","first-page":"11732","DOI":"10.3390\/ijms241411732","volume":"24","author":"A Antonioni","year":"2023","unstructured":"Antonioni A, Raho EM, Lopriore P, Pace AP, Latino RR, Assogna M, et al. Frontotemporal dementia, where do we stand? A narrative review. Int J Mol Sci. 2023;24:11732 https:\/\/doi.org\/10.3390\/ijms241411732","journal-title":"Int J Mol Sci"},{"key":"3824_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijchp.2025.100544","volume":"25","author":"S Pauligk","year":"2025","unstructured":"Pauligk S, Seidel M, Ritschel F, Geisler D, Doose A, Boehm I, et al. Overcontrol in anorexia nervosa: elevated prefrontal activity and amygdala connectivity in a working memory task with food distractors. Int J Clin Heal Psychol. 2025;25:100544 https:\/\/doi.org\/10.1016\/j.ijchp.2025.100544","journal-title":"Int J Clin Heal Psychol"},{"key":"3824_CR136","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/b978-0-12-381326-8.00010-7","volume":"95","author":"O Kambur","year":"2010","unstructured":"Kambur O, M\u00e4nnist\u00f6 PT. Catechol-O-methyltransferase and pain. Int Rev Neurobiol. 2010;95:227\u201379. https:\/\/doi.org\/10.1016\/b978-0-12-381326-8.00010-7","journal-title":"Int Rev Neurobiol"},{"key":"3824_CR137","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.biopsych.2005.10.024","volume":"60","author":"EM Tunbridge","year":"2006","unstructured":"Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry. 2006;60:141\u201351. https:\/\/doi.org\/10.1016\/j.biopsych.2005.10.024","journal-title":"Biol Psychiatry"},{"key":"3824_CR138","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1001\/archpsyc.63.12.1396","volume":"63","author":"EM Drabant","year":"2006","unstructured":"Drabant EM, Hariri AR, Meyer-Lindenberg A, Munoz KE, Mattay VS, Kolachana BS, et al. Catechol O-methyltransferase Val158Met genotype and neural mechanisms related to affective arousal and regulation. Arch Gen Psychiatry. 2006;63:1396\u2013406. https:\/\/doi.org\/10.1001\/archpsyc.63.12.1396","journal-title":"Arch Gen Psychiatry"},{"key":"3824_CR139","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/s0306-4522(02)00556-0","volume":"116","author":"M Matsumoto","year":"2003","unstructured":"Matsumoto M, Weickert CS, Akil M, Lipska BK, Hyde TM, Herman MM, et al. Catechol O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience. 2003;116:127\u201337. https:\/\/doi.org\/10.1016\/s0306-4522(02)00556-0","journal-title":"Neuroscience"},{"key":"3824_CR140","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1073\/pnas.92.7.2446","volume":"92","author":"YY Huang","year":"1995","unstructured":"Huang YY, Kandel ER. D1\/D5 receptor agonists induce a protein synthesis-dependent late potentiation in the CA1 region of the hippocampus. Proc Natl Acad Sci. 1995;92:2446\u201350. https:\/\/doi.org\/10.1073\/pnas.92.7.2446","journal-title":"Proc Natl Acad Sci"},{"key":"3824_CR141","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1124\/pr.115.010512","volume":"67","author":"AFT Arnsten","year":"2015","unstructured":"Arnsten AFT, Wang M, Paspalas CD, Witkin JM. Dopamine\u2019s actions in primate prefrontal cortex: challenges for treating cognitive disorders. Pharmacol Rev. 2015;67:681\u201396. https:\/\/doi.org\/10.1124\/pr.115.010512","journal-title":"Pharmacol Rev"},{"key":"3824_CR142","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/30245","volume":"393","author":"RC Saunders","year":"1998","unstructured":"Saunders RC, Kolachana BS, Bachevalier J, Weinberger DR. Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine. Nature. 1998;393:169\u201371. https:\/\/doi.org\/10.1038\/30245","journal-title":"Nature"},{"key":"3824_CR143","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/286074a0","volume":"286","author":"CJ Pycock","year":"1980","unstructured":"Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature. 1980;286:74\u201377. https:\/\/doi.org\/10.1038\/286074a0","journal-title":"Nature"},{"key":"3824_CR144","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.neuron.2006.01.023","volume":"49","author":"C Kellendonk","year":"2006","unstructured":"Kellendonk C, Simpson EH, Polan HJ, Malleret G, Vronskaya S, Winiger V, et al. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron. 2006;49:603\u201315. https:\/\/doi.org\/10.1016\/j.neuron.2006.01.023","journal-title":"Neuron"},{"key":"3824_CR145","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1523\/jneurosci.23-06-02008.2003","volume":"23","author":"M Akil","year":"2003","unstructured":"Akil M, Kolachana BS, Rothmond DA, Hyde TM, Weinberger DR, Kleinman JE. Catechol-O-methyltransferase genotype and dopamine regulation in the human brain. J Neurosci. 2003;23:2008\u201313. https:\/\/doi.org\/10.1523\/jneurosci.23-06-02008.2003","journal-title":"J Neurosci"},{"key":"3824_CR146","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/nn1438","volume":"8","author":"A Meyer-Lindenberg","year":"2005","unstructured":"Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, McInerney-Leo A, Nussbaum R, et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nat Neurosci. 2005;8:594\u20136. https:\/\/doi.org\/10.1038\/nn1438","journal-title":"Nat Neurosci"},{"key":"3824_CR147","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.2174\/1570159x18666201023154049","volume":"19","author":"J Ma","year":"2021","unstructured":"Ma J, Zhao M, Zhou W, Li M, Huai C, Shen L, et al. Association between the COMT Val158Met polymorphism and antipsychotic efficacy in schizophrenia: an updated meta-analysis. Curr Neuropharmacol. 2021;19:1780\u201390. https:\/\/doi.org\/10.2174\/1570159x18666201023154049","journal-title":"Curr Neuropharmacol"},{"key":"3824_CR148","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.biopsych.2017.10.030","volume":"83","author":"J Hiser","year":"2018","unstructured":"Hiser J, Koenigs M. The multifaceted role of the ventromedial prefrontal cortex in emotion, decision making, social cognition, and psychopathology. Biol Psychiatry. 2018;83:638\u201347. https:\/\/doi.org\/10.1016\/j.biopsych.2017.10.030","journal-title":"Biol Psychiatry"},{"key":"3824_CR149","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1093\/brain\/awad263","volume":"146","author":"N Clairis","year":"2023","unstructured":"Clairis N, Lopez-Persem A. Debates on the dorsomedial prefrontal\/dorsal anterior cingulate cortex: insights for future research. Brain. 2023;146:4826\u201344. https:\/\/doi.org\/10.1093\/brain\/awad263","journal-title":"Brain"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03824-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:31:03Z","timestamp":1787160663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-026-03824-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":149,"alternative-id":["3824"],"URL":"https:\/\/doi.org\/10.1038\/s41380-026-03824-9","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EMT is a full-time employee of Boehringer Ingelheim and has previously provided consultancy to Boehinger Ingelheim and ONO Pharma, and received unrestricted educational funding from J&J Innovations, and Boehringer Ingelheim and Biogen via the Psychiatry Consortium of the Medicines Discovery Catapult. GVC is a scientific advisor for LongTermGevity, Inc. and owns stock options in the company. DRW is on the Scientific Advisory Board (SAB) of Pasithea Therapeutics, and until September, 2025, had been on the SAB of Sage Therapeutics.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}